When: March 6th, 2026 12 PM – 3:15 ET
Where: Online
Speakers: Temple Morris, LCSW-C, Miranda Morris, PhD
Description:
Psychedelic-assisted therapy may represent an upcoming paradigm shift in the treatment of mental health problems as recent clinical trials have demonstrated strong evidence of their therapeutic benefits. This workshop will provide health care professionals an overview of the ethical issues involved in this new clinical area. While psychedelics are currently prohibited substances in most countries, the growing popularity of their therapeutic potential is leading many people to use psychedelics on their own rather than waiting for legal medical access. Therapists therefore have an ethical duty to meet this need by providing support for clients using psychedelics. However, incorporating psychedelics into traditional psychotherapy poses some risk given their prohibited status, and many therapists are unsure of how they might practice in this area. This workshop explicates such risks and describes ways in which therapists can mitigate them and strive to practice within legal and ethical boundaries. A harm reduction approach will be emphasized as a useful framework for conducting therapy around clients’ use of psychedelics.
In this workshop, we will review the history of the use of psychedelics with an appreciation for their long-standing use by many indigenous cultures. Differences between the most common psychedelics will be explored as will their psychological and physical effects. The two major waves of psychedelic research will be summarized, with emphasis on more recent and rigorous clinical trials, particularly those using contextual behavioral approaches. In addition, The current legal status of psychedelics will be reviewed, including Oregon’s recent passing of an initiative to legalize psilocybin-assisted therapy. Finally, diversity issues around lack of access for underserved and non-majority populations will be explored. This workshop will emphasize the need to prioritize diversity and accessibility as psychedelic assisted psychotherapy becomes more widely available.
This workshop is for clinicians who are new to this topic area as well as clinicians who are familiar with the psychedelics medicine/psychotherapy literature and who are interested in the ethical implications of this work – past, present and future. Though primarily didactic, this workshop will include experiential exercises and small group work to deepen their understanding of the issues related to psychedelics as a treatment tool.
Cost:
| Early Registration (by February 6th) | $70 |
| Standard Registration | $95 |
| Student | $25 |
| CE Certificate (3 hours) | $10 |
Registration fee covers instruction.
CE Credits
- This activity is has approval for 3 Ethics CE credits for psychologists and counselors (who can use APA CE credits)
- This activity has approval for 3 Ethics CE credits for social workers.
- Weaver and Associates, provider #2017, is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved as ACE providers. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. Weaver and Associates maintains responsibility for this course. ACE provider approval period: 12/15/25-12/15/26. Social workers completing this course receive 3 clinical continuing education credits.
CEs are awarded contingent on timely post-event paperwork submission by event organizers
Refunds: A $25 processing fee will be charged for registration refunds up to February 15th. We regret that after February 15, refunds cannot be made, but you may request credit toward a future program. If you need a refund, please contact us via email at drmirandamorris@gmail.com.
Learning Objectives
After attending this training you will be able to:
- Identify and describe at least 3 harm reduction strategies related to the use of psychedelic medicines
- Describe at least 2 obstacles related to lack of access for underserved and non-majority populations
- Describe the safety and addiction potential of at least one psychedelic medicine (e.g., ketamine, psilocybin, MDMA) when administered by trained professionals
Instructor Bios
Temple Morris, LCSW-C, is a clinical social worker based in Bethesda, MD, specializing in Acceptance and Commitment Therapy (ACT) and Psychedelic Harm Reduction and Integration therapy (HRIT). She is co-founder and trainer at Perspective Retreats, which offers professional training retreats integrating ACT with psychedelic-assisted psychotherapy, and co-founder and therapist at True North Therapy & Training. Temple is MAPS-trained in psychedelic-assisted therapy and serves as a consultant therapist and clinical investigator at Sunstone Therapies in Rockville, MD, where she works on multiple psychedelic-assisted therapy trials.
Temple is engaged in the psychedelic therapy community through her work with the Association of Contextual Behavioral Science (ACBS), where she serves on the board of the Psychedelic Special Interest Group (Psychedelic SIG) and co-facilitates both a monthly psychedelic HRIT peer consultation group and the monthly Psychedelic SIG member meeting. She is also a founding member of Psychedelic-Assisted Therapy & Healing (PATH), a collective of local clinicians dedicated to providing training and education around legal psychedelic medicines and ensuring equitable access to ketamine-assisted therapy.
Miranda Morris, PhD, is a psychologist based in Bethesda, MD, and a Peer Reviewed ACT Trainer who conducts regular workshops in Acceptance and Commitment Therapy (ACT) and related therapies including Functional Analytic Psychotherapy (FAP) and Relational Frame Theory (RFT). She is co-founder and trainer at Perspective Retreats, which offers professional training retreats integrating ACT with psychedelic-assisted psychotherapy, and co-founder of True North Therapy & Training, a group dedicated to sharing contextual behavioral therapies with clients, practitioners, and the broader community. Additionally, Miranda is a founding member of Psychedelic-Assisted Therapy & Healing (PATH), a collective of local clinicians dedicated to providing training and education around legal psychedelic medicines and ensuring equitable access to ketamine-assisted therapy. She is active in the contextual behavioral science community and is a Past President of the Board of the Association of Contextual Behavioral Science (ACBS). She is also a member of the Mid Atlantic Chapter of ACBS and their ACT Carolinas affiliate.
FOR MORE INFORMATION Please email Admin@truenorthact.com
No commercial support was obtained for this CE program or for the instruction content that could be construed as a conflict of interest. No commercial support is being sought for an endorsement of any product (e.g., books, programs, etc.).